JP2020527564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527564A5 JP2020527564A5 JP2020502170A JP2020502170A JP2020527564A5 JP 2020527564 A5 JP2020527564 A5 JP 2020527564A5 JP 2020502170 A JP2020502170 A JP 2020502170A JP 2020502170 A JP2020502170 A JP 2020502170A JP 2020527564 A5 JP2020527564 A5 JP 2020527564A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- stamp
- seq
- infection
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 154
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
- 238000006467 substitution reaction Methods 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 51
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 50
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 50
- 230000002209 hydrophobic effect Effects 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 48
- 241000894006 Bacteria Species 0.000 claims description 45
- 208000015181 infectious disease Diseases 0.000 claims description 41
- 108010078777 Colistin Proteins 0.000 claims description 40
- 229960003346 colistin Drugs 0.000 claims description 40
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 40
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 40
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 40
- 208000035143 Bacterial infection Diseases 0.000 claims description 39
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 37
- 230000003115 biocidal effect Effects 0.000 claims description 27
- -1 4-pentenyl Chemical group 0.000 claims description 26
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 24
- 230000007694 nephrotoxicity Effects 0.000 claims description 24
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 24
- 238000012217 deletion Methods 0.000 claims description 23
- 230000037430 deletion Effects 0.000 claims description 23
- 238000003780 insertion Methods 0.000 claims description 23
- 230000037431 insertion Effects 0.000 claims description 23
- 150000001768 cations Chemical class 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 8
- 206010001488 Aggression Diseases 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 206010061259 Klebsiella infection Diseases 0.000 claims description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 4
- 241000588697 Enterobacter cloacae Species 0.000 claims description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 241000588770 Proteus mirabilis Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 206010040550 Shigella infections Diseases 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- 229940126575 aminoglycoside Drugs 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 229960003104 ornithine Drugs 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 229960003165 vancomycin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- 206010061041 Chlamydial infection Diseases 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 206010062204 Moraxella infection Diseases 0.000 claims description 3
- 208000031548 Moraxellaceae Infections Diseases 0.000 claims description 3
- 206010035148 Plague Diseases 0.000 claims description 3
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 3
- 206010054138 Stenotrophomonas infection Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims description 2
- 208000037887 cell injury Diseases 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 230000005660 hydrophilic surface Effects 0.000 claims description 2
- 230000005661 hydrophobic surface Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 229940127557 pharmaceutical product Drugs 0.000 claims 5
- 241000158640 Acanthodactylus aureus Species 0.000 claims 2
- 241001135699 Arcanobacterium Species 0.000 claims 2
- 241001660259 Cereus <cactus> Species 0.000 claims 2
- 206010001427 Enterobacter infections Diseases 0.000 claims 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- 208000022338 anthrax infection Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 241000511654 Actinomyces gerencseriae Species 0.000 claims 1
- 241000186041 Actinomyces israelii Species 0.000 claims 1
- 208000006448 Buruli Ulcer Diseases 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000186216 Corynebacterium Species 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 206010024179 Legionella infections Diseases 0.000 claims 1
- 208000004023 Legionellosis Diseases 0.000 claims 1
- 241000186362 Mycobacterium leprae Species 0.000 claims 1
- 241000178382 Mycobacterium lepromatosis Species 0.000 claims 1
- 206010066289 Mycobacterium ulcerans infection Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 241000186336 Pseudopropionibacterium propionicum Species 0.000 claims 1
- 206010039438 Salmonella Infections Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000193985 Streptococcus agalactiae Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 1
- 206010048249 Yersinia infections Diseases 0.000 claims 1
- 208000035994 Yersinia pseudotuberculosis Infections Diseases 0.000 claims 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 claims 1
- 150000001336 alkenes Chemical group 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 206010039447 salmonellosis Diseases 0.000 claims 1
- 210000004926 tubular epithelial cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 description 16
- 230000002949 hemolytic effect Effects 0.000 description 11
- 101000958205 Hogna carolinensis M-lycotoxin-Hc1a Proteins 0.000 description 8
- 108010036176 Melitten Proteins 0.000 description 8
- 108010025307 buforin II Proteins 0.000 description 8
- 108060001132 cathelicidin Proteins 0.000 description 8
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 8
- 102000014509 cathelicidin Human genes 0.000 description 8
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- STDPEXNTSMXASR-FVIUBGISSA-N lycotoxin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 STDPEXNTSMXASR-FVIUBGISSA-N 0.000 description 8
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 8
- CTVQQQPWNOVEAG-QDOPKCMFSA-N pardaxin Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CN)C1=CC=CC=C1 CTVQQQPWNOVEAG-QDOPKCMFSA-N 0.000 description 8
- 108010062940 pexiganan Proteins 0.000 description 8
- KGZGFSNZWHMDGZ-KAYYGGFYSA-N pexiganan Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 KGZGFSNZWHMDGZ-KAYYGGFYSA-N 0.000 description 8
- 229950001731 pexiganan Drugs 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 101150004219 MCR1 gene Proteins 0.000 description 6
- KENGXPKQZMFVCK-PWWQNGLPSA-N clavanin b Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 KENGXPKQZMFVCK-PWWQNGLPSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000604933 Bdellovibrio Species 0.000 description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 5
- 229960003085 meticillin Drugs 0.000 description 5
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 241000589242 Legionella pneumophila Species 0.000 description 3
- 241000588621 Moraxella Species 0.000 description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- 241000122971 Stenotrophomonas Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940115932 legionella pneumophila Drugs 0.000 description 3
- 229960002260 meropenem Drugs 0.000 description 3
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 2
- 241000251752 Myxine glutinosa Species 0.000 description 2
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 2
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 2
- 229960003169 biapenem Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 2
- 229960000895 doripenem Drugs 0.000 description 2
- 229960002770 ertapenem Drugs 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 2
- 229960002182 imipenem Drugs 0.000 description 2
- 229950011346 panipenem Drugs 0.000 description 2
- SNUDIPVBUUXCDG-QHSBEEBCSA-N tebipenem pivoxil Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 SNUDIPVBUUXCDG-QHSBEEBCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022152457A JP2022177234A (ja) | 2017-07-19 | 2022-09-26 | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534464P | 2017-07-19 | 2017-07-19 | |
| US62/534,464 | 2017-07-19 | ||
| US201862644114P | 2018-03-16 | 2018-03-16 | |
| US62/644,114 | 2018-03-16 | ||
| PCT/US2018/042640 WO2019018499A2 (en) | 2017-07-19 | 2018-07-18 | ANTIMICROBIAL PEPTIDES STABILIZED FOR THE TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152457A Division JP2022177234A (ja) | 2017-07-19 | 2022-09-26 | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527564A JP2020527564A (ja) | 2020-09-10 |
| JP2020527564A5 true JP2020527564A5 (https=) | 2021-11-04 |
| JP7305614B2 JP7305614B2 (ja) | 2023-07-10 |
Family
ID=63371759
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502170A Active JP7305614B2 (ja) | 2017-07-19 | 2018-07-18 | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
| JP2022152457A Pending JP2022177234A (ja) | 2017-07-19 | 2022-09-26 | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022152457A Pending JP2022177234A (ja) | 2017-07-19 | 2022-09-26 | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11325955B2 (https=) |
| EP (1) | EP3655105A2 (https=) |
| JP (2) | JP7305614B2 (https=) |
| AU (1) | AU2018304230A1 (https=) |
| CA (1) | CA3067047A1 (https=) |
| WO (1) | WO2019018499A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3014442A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| AU2018304230A1 (en) | 2017-07-19 | 2020-02-06 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
| CN110283253B (zh) * | 2019-07-12 | 2020-04-10 | 东北农业大学 | 一种猪源衍生杂合抗菌肽mdp-2及其制备方法和应用 |
| US20230116760A1 (en) * | 2019-12-16 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Structurally-stabilized oncolytic peptides and uses thereof |
| CA3179872A1 (en) * | 2020-04-22 | 2021-10-28 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof |
| WO2022037681A1 (zh) * | 2020-08-21 | 2022-02-24 | 中国科学院微生物研究所 | 抗微生物肽及其应用 |
| JP2024512165A (ja) * | 2021-03-12 | 2024-03-18 | リティカ セラピューティクス，インコーポレーテッド | ステープルド抗微生物ペプチド（ｓｔａｍｐ）およびそれらの使用 |
| US20250313820A1 (en) | 2021-10-22 | 2025-10-09 | In2Cure Ab | Peptides with multivalent effects |
| CN114395026B (zh) * | 2022-01-27 | 2023-11-21 | 福州大学 | 一种基于理性设计策略构建的广谱抗菌肽 |
| CN114432428B (zh) * | 2022-02-24 | 2024-07-23 | 西北农林科技大学 | PGLa提高细菌对抗生素的敏感性和延缓细菌耐药性产生的应用 |
| WO2024223868A1 (en) | 2023-04-26 | 2024-10-31 | In2Cure Ab | Peptides with multivalent effects for topical use |
| CN117756904B (zh) * | 2023-12-22 | 2024-05-24 | 潍坊医学院 | 一种订书肽及其应用 |
| US12202868B1 (en) | 2024-05-16 | 2025-01-21 | King Saud University | Stapled and specifically targeted antimicrobial peptide |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861478A (en) | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| US5912231A (en) | 1989-07-07 | 1999-06-15 | Scripps Clinic And Research Foundation | Substitution analogues of magainin peptides |
| WO1991000869A1 (en) * | 1989-07-07 | 1991-01-24 | Scripps Clinic And Research Foundation | Substitution analogues of magainin peptides |
| US5607914A (en) | 1993-01-13 | 1997-03-04 | Pioneer Hi-Bred International, Inc. | Synthetic antimicrobial peptides |
| US5561107A (en) | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5885829A (en) | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| PT1053019E (pt) | 1998-01-07 | 2004-04-30 | Debio Rech Pharma Sa | Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos |
| HUP0100575A3 (en) | 1998-01-21 | 2003-03-28 | Merck Sharp & Dohme Ltd Hoddes | Triazolo-pyridazine derivatives as ligands for gaba receptors |
| KR100314721B1 (ko) | 1998-01-22 | 2001-11-23 | 김일웅 | 생물학적 활성이 있는 신규한 펩타이드 |
| AU5006499A (en) | 1998-07-23 | 2000-02-14 | Intrabiotics Pharmaceuticals, Inc. | Compositions and methods for the treatment or prevention of pulmonary infections |
| US6288212B1 (en) | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
| US6562785B1 (en) | 1999-03-23 | 2003-05-13 | Howard M. Shapiro | Method for overcoming bacterial antibiotic resistance |
| DE19914817A1 (de) | 1999-03-31 | 2000-10-05 | Petry Genmedics Gmbh Dr | Wirkstoffe zur Bekämpfung von bakteriellen Infektionserkrankungen |
| US6262071B1 (en) | 1999-06-29 | 2001-07-17 | Smithkline Beecham Corporation | Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria |
| JP2003531101A (ja) | 1999-06-29 | 2003-10-21 | スミスクライン・ビーチャム・コーポレイション | 細菌に対するフルオロキノロン化合物の使用法 |
| US20030143234A1 (en) | 1999-08-20 | 2003-07-31 | Wenyuan Shi | Anti-microbial targeting chimeric pharmaceutical |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| BR0001870B1 (pt) | 2000-05-29 | 2014-02-25 | Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas | |
| CA2441562C (en) | 2001-03-28 | 2013-05-14 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
| CN1158304C (zh) * | 2001-05-10 | 2004-07-21 | 上海华谊生物技术有限公司 | 蛙皮抗菌肽衍生物 |
| KR100614714B1 (ko) | 2001-06-15 | 2006-08-21 | 에프. 호프만-라 로슈 아게 | ｇｐ41 단편의 아세틸화 |
| US6620954B1 (en) | 2002-03-25 | 2003-09-16 | Eastman Chemical Company | Phosphinometallocenylamides as novel ligands for asymmetric catalysis |
| WO2003083441A2 (en) | 2002-03-29 | 2003-10-09 | Buck Institute | Identification of apoptotic peptides and methods of use thereof |
| ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
| US7745390B2 (en) | 2005-05-23 | 2010-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Antimicrobial peptides |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| WO2008058575A1 (de) | 2006-11-17 | 2008-05-22 | Osram Gesellschaft mit beschränkter Haftung | Modulares flächen- leuchtsystem |
| WO2008086042A2 (en) | 2007-01-10 | 2008-07-17 | Chisari Francis V | Preventing infection by a measles or respiratory syncytial virus |
| DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| US8592377B2 (en) * | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| AU2008256689A1 (en) | 2007-05-24 | 2008-12-04 | New York Blood Center Inc. | Rapidly dispersible vaginal tablet that provides a bioadhesive gel |
| CA2700925C (en) | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| EP2247606B1 (en) | 2008-01-23 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of viral infections |
| US20100069308A1 (en) | 2008-06-06 | 2010-03-18 | Chorny Iiya | Surfaces containing antibacterial polymers |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| EP2346521A4 (en) | 2008-10-06 | 2012-06-20 | Univ Colorado Regents | PEPTIDES AND USE METHOD THEREFOR |
| BRPI0920899A2 (pt) | 2008-11-24 | 2016-04-26 | Aileron Therapeutics Inc | macrociclos peptidomiméticos com propriedades melhoradas |
| GB0821687D0 (en) | 2008-11-28 | 2008-12-31 | Secr Defence | Peptides |
| KR20100065639A (ko) | 2008-12-08 | 2010-06-17 | 건국대학교 산학협력단 | 새로운 피시딘 유도체 항생 펩타이드 및 그 용도 |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| AU2010263056B2 (en) | 2009-06-18 | 2016-01-07 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| DK2445515T3 (en) | 2009-06-26 | 2016-07-04 | Univ Leuven Kath | antimicrobial agents |
| US20130139930A1 (en) | 2009-12-18 | 2013-06-06 | Latitude 18, Inc. | Inorganic phosphate corrosion resistant coatings |
| EP2590997B1 (en) | 2010-07-09 | 2018-04-04 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
| AU2012242502B2 (en) | 2011-04-15 | 2016-07-28 | Dana-Farber Cancer Institute, Inc. | Targeting deregulated WNT signaling in cancer using stabilized alpha-helices of BCL-9 |
| DE102012203547A1 (de) | 2012-03-07 | 2013-09-12 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Antimikrobielle Peptide |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| WO2013049567A1 (en) | 2011-09-29 | 2013-04-04 | The Broad Institute, Inc. | Compounds for the treatment of mycobacterial infections |
| US8669226B2 (en) | 2011-10-07 | 2014-03-11 | Morehouse School Of Medicine | Antimicrobial compositions and methods of use thereof |
| CA2862391C (en) | 2011-12-29 | 2023-10-10 | Loren D. Walensky | Stabilized antiviral fusion helices |
| WO2013148677A1 (en) | 2012-03-26 | 2013-10-03 | University Of Florida Research Foundation, Inc. | Antimicrobial compounds and their use in treating plant disease |
| RU2694758C2 (ru) | 2012-12-20 | 2019-07-16 | Раджив Бхушан | Антимикробные композиции |
| CN103164738B (zh) | 2013-02-06 | 2015-09-30 | 厦门盛华电子科技有限公司 | 一种基于移动支付多通道数字认证的手机用户识别卡 |
| EP3391898A3 (en) | 2013-03-13 | 2019-02-13 | President and Fellows of Harvard College | Stapled and stitched polypeptides and uses thereof |
| AU2014227824B2 (en) | 2013-03-15 | 2018-09-27 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| EP2970418A4 (en) | 2013-03-15 | 2016-08-17 | Dana Farber Cancer Inst Inc | STABILIZED EZH2 PEPTIDES |
| WO2015070912A1 (en) | 2013-11-14 | 2015-05-21 | Lysando Ag | Modified el188 endolysin sequence |
| EP3096616B1 (en) | 2014-01-24 | 2020-04-29 | The Regents of the University of Colorado, a Body Corporate | Dermaseptin-type and piscidin-type antimicrobial peptides |
| WO2015138494A1 (en) | 2014-03-10 | 2015-09-17 | Georges Belfort | Anti-microbial peptides and method for designing novel anti-microbial peptides |
| US10507227B2 (en) | 2014-04-15 | 2019-12-17 | The Hospital For Sick Children | Cationic antimicrobial peptides |
| EP3317294B1 (en) | 2015-07-02 | 2023-03-15 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| US20190048038A1 (en) | 2016-02-23 | 2019-02-14 | Dana-Farber Cancer Institute, Inc. | Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting |
| CA3014442A1 (en) | 2016-02-29 | 2017-09-08 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| AU2018304230A1 (en) | 2017-07-19 | 2020-02-06 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
-
2018
- 2018-07-18 AU AU2018304230A patent/AU2018304230A1/en not_active Abandoned
- 2018-07-18 EP EP18759770.3A patent/EP3655105A2/en active Pending
- 2018-07-18 WO PCT/US2018/042640 patent/WO2019018499A2/en not_active Ceased
- 2018-07-18 CA CA3067047A patent/CA3067047A1/en active Pending
- 2018-07-18 US US16/631,315 patent/US11325955B2/en active Active
- 2018-07-18 JP JP2020502170A patent/JP7305614B2/ja active Active
-
2022
- 2022-09-26 JP JP2022152457A patent/JP2022177234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527564A5 (https=) | ||
| Moellering Jr | MRSA: the first half century | |
| AU2019222918B2 (en) | Antimicrobial peptides and methods of use thereof | |
| Mohsin | The under reported issue of antibiotic-resistance in food-producing animals in Pakistan. | |
| Sinha et al. | Efflux pumps: gatekeepers of antibiotic resistance in Staphylococcus aureus biofilms | |
| Ovchinnikov et al. | Successful development of bacteriocins into therapeutic formulation for treatment of MRSA skin infection in a murine model | |
| Kumar et al. | Molecular mechanisms of bacterial resistance to antimicrobial agents | |
| Sridevi et al. | Inhibitory effects of reserpine against efflux pump activity of antibiotic resistance bacteria | |
| Beier et al. | Disinfectant and antimicrobial susceptibility studies of the foodborne pathogen Campylobacter jejuni isolated from the litter of broiler chicken houses | |
| US20130183323A1 (en) | Targeted antibiotic and antimicrobial treatments for personalized administration | |
| JPH11508265A (ja) | 抗生物質抵抗性グラム陽性細菌の制御および感染治療の方法 | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| JP2008528761A (ja) | 抗菌剤としてのβ−シクロデキストリン誘導体 | |
| CN105377250A (zh) | 用于对抗抗菌剂抗性细菌的组合物和方法 | |
| Shayesteh et al. | In vitro anti-biofilm activity of bacteriocin from a marine Bacillus sp. strain Sh10 against Proteus mirabilis | |
| JP2017533177A5 (https=) | ||
| JP2017522280A (ja) | 特に獣医学分野用の消毒剤および抗微生物組成物 | |
| Panlilio et al. | Antibiofilm Activity of PEGylated Branched Polyethylenimine | |
| Mohammed et al. | Review on livestock associated Methicillin resistant Staphylococcus aureus and its zoonotic importance | |
| AU2016269417B2 (en) | Disinfectant and antimicrobial compositions, in particular for the veterinary field | |
| US10279017B2 (en) | Use of metalloproteinase inhibitors against bacterial infections | |
| US9393250B2 (en) | Phthalocyanine compounds useful as RecA inhibitors and methods of using same | |
| Majumder et al. | Antibiotic Adjuvants–A Review Article | |
| Gottschalk et al. | The lysine-peptoid hybrid LP5 maintain activity under physiological conditions and affects virulence gene expression in Staphylococcus aureus | |
| JP6749617B2 (ja) | 抗菌性合剤の探索方法 |